| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
Primary chondrosarcoma (CS) is the second most common primary malignant tumor of bone. Despite the continuous development and progress made in diagnostic techniques and auxiliary treatment, there is still no good treatment for CS at present. To develop new treatment for CS, we studied the oncogenesis of CS by focusing on the CS stem cells. We found that S100A4 and type I collgen were expressed in CS cell line that would have phenotype of CS stem cell by spheroid colony assay. We also established drug-resistance CS cell lines and the cell line expressed P-glycoprotein (Pgp), indicating that Pgp was able to be a candidate of molecular target of CS treatment.
|
